The University of Manchester (UoM) is one of the largest single-site universities in the UK, with 40,000 students from almost every country in the world. With world-leading research and social responsibility at its heart, Manchester is a place to innovate, to lead and to make a difference. A Russell Group university, it is ranked in the top 30 universities in the world (QS World University Rankings 2019). UoM and Manchester University Foundation Trust (MFT, linked 3rd party) host the Versus Arthritis Centre for Epidemiology and the NIHR Common Disease BioResource for IMIDs. The CoInvestigators (Co-I) are part of an integrated multidisciplinary team with world-leading expertise in clinical epidemiology, digital epidemiology and neurocognitive function.
Main tasks in the project
In WP2, UoM will provide clinical insight and knowledge to contribute to the management and recruitment of rheumatic patients.
In WP6, UoM will manage recruitment for the longitudinal study to ensure recruitment targets are reached on time and within budget. We will provide data and interpretation of digital fatigue endpoints from the QUASAR study.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853981. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and PARKINSON’S DISEASE SOCIETY OF THE UNITED KINGDOM LBG.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.